BIOHEART-B (02185.HK): Appoints Former Medtronic and ReCor Medical Executive Giorgio Gobbi as VP of Global Therapy Development at AngioCare

NewTimeSpace News: On 7 September 2026, Shanghai Bio-heart Biological Technology Co., Ltd. (stock code: 02185) announced that Mr. Giorgio Gobbi, a former senior executive at Medtronic and ReCor Medical, has joined AngioCare, the company's non-wholly owned subsidiary, as Vice President of Global Therapy Development, with full responsibility for the global therapy development of the Iberis® renal denervation (RDN) system.

Mr. Gobbi holds an M.D. degree and has over twenty years of experience in cardiovascular and metabolic diseases. He previously served at Ardian, Medtronic and ReCor Medical, all benchmark companies in the RDN field, and is among the earliest industry leaders in the field, with mature experience in clinical evidence building and global therapy promotion. His responsibilities at AngioCare include global KOL academic collaboration, formation of expert advisory boards, strategic planning of post-market global clinical programs, and standardization of international training systems.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.